Using additional robust, quantitative, physiologic, and clinically relevant readouts, our work confirms and extends prior work showing that global KO or pharmacologic inhibition of S100A4 protects against bleomycin-induced pulmonary fibrosis in mice (45, 46). Here, S100A4 is linked to pulmonary fibrosis.